Search for a command to run...
ABSTRACT Adeno-associated viral (AAV)–mediated overexpression of human wildtype α-synuclein (α-syn) in the substantia nigra (SN) is a widely used approach to model Parkinson’s disease (PD) in rodents. However, variability in the ability of AAV-based systems to induce nigrostriatal pathology and motor deficits has limited reproducibility across studies, especially in mice. Here, we systematically optimized key vector features – AAV serotype, promoter, viral titer – to establish a highly efficient and reliable mouse model of PD. We compared the tropism and expression efficiency of mixed AAV2/1 and AAV2/rh10 serotypes combined with three promoters – CMV enhancer/chicken β-actin (CBA), human Synapsin (hSYN), and rat Tyrosine Hydroxylase (TH) – to drive human α-syn gene (SNCA) expression in nigral dopaminergic neurons. The AAV.TH.SNCA vector, delivered at an optimized titer, achieved selective and sustained α-syn overexpression in nigral neurons, resulting in nigro-striatal neurochemical changes and progressive motor deficits preceding overt neuronal loss. Fine tuning α-syn expression proved critical for detecting early disease processes: lower AAV.TH.SNCA titer induced early pathological signatures, including α-syn hyperphosphorylation and neuroinflammation, whereas higher titers produced robust nigrostriatal degeneration not achieved with other promoter constructs. Notably, we demonstrate that motor and neurochemical impairments can occur prior to dopaminergic cell death, implicating microglial activation and α-syn pathology as primary drivers of dysfunction. This observation is consistent with human genetic evidence showing that triplication of the wild-type SNCA gene alone can cause Parkinsonian pathology, highlighting that our model enables the use of a single experimental reagent to investigate the molecular, cellular, and behavioral consequences of controlled increases in α-syn expression. This novel AAV.TH.SNCA model provides a powerful and versatile platform for investigating mechanisms of a α-syn–mediated neurotoxicity and for evaluating disease modifying interventions targeting early, pre-degenerative stages of PD. Highlights Titrated α-syn expression uncouples early dysfunction from dopaminergic neuron loss AAV2/rh10-TH-SNCA model captures prodromal and degenerative PD stages Motor deficits arise from α-syn pathology and nigral molecular changes before neurodegeneration.